ELISA Market Size, Share, Forecast, & Trends Analysis by Type (Direct, Sandwich, Competitive) Offering (Analyzer, Software) Technology (Chemiluminescence, Colorimetry, Fluorescence) Application (Research, Diagnostic) End User

Description

List of Tables

ELISA Market Size, Share, Forecast, & Trends Analysis by Type (Direct, Sandwich, Competitive) Offering (Analyzer, Software) Technology (Chemiluminescence, Colorimetry, Fluorescence) Application (Research, Diagnostic) End User-Global Forecast to 2031

The ELISA market is projected to reach $32.69 billion by 2031 at a CAGR of 6.1% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the ELISA market is driven by the increasing number of chronic and infectious diseases, growing ELISA application in clinical settings, advancements in ELISA, and the growing application of ELISA in food industries. However, the chances of false positive results and high ELISA antibody preparation costs restrain the growth of this market.

Furthermore, growing research in emerging countries, rising R&D activities for biomarker detection, and the increasing focus on vaccine development are expected to generate market growth opportunities. However, stringent regulations for ELISA product approval and the availability and usage of alternative technologies for disease diagnosis are major challenges in the ELISA market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the past three to four years. The key players operating in the ELISA market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), bioMerieux SA (France), Revvity Inc. (U.S.), QuidelOrtho Corporation (U.S.), Becton, Dickinson and Company (U.S.), Repligen Corporation (U.S.), BioLegend (U.S.), and Bio-Techne Corporation (U.S.).

Among all the ELISA types studied in this report, in 2024, the indirect ELISA segment is expected to account for the largest share of 43.5% of the ELISA market. The largest share of this segment is attributed to the highly sensitive nature of indirect ELISA and the ability of ELISA to identify antigens in low-concentration solutions and the advantages of the indirect ELISA methods such as cost-effectiveness, easy operation, and most preferable for all applications. The indirect method helps in disease diagnoses such as Lyme disease and HIV, which minimizes the possibility of false positive results.

Among all the ELISA offerings studied in this report, in 2024, the kits & assays segment is expected to account for the largest share of 85.2% of the ELISA market. The larger market share of this segment is attributed to the increased use of ELISA kits & assays for biomarker detection and several chronic and infectious diseases, the availability of a wide range of assay kits for research purposes, and the wide adoption of ELISA assay kits in drug discovery.

Among all the technologies studied in this report, in 2024, the colorimetric ELISA segment is expected to account for the largest share of the ELISA market. Colorimetric ELISA is widely preferred due to its advantages such as low reagent consumption, simplicity, cost-effectiveness, broad range of applications, ease of performance, and requirement of less equipment to process. Additionally, these assays are compatible with various types of samples for complex research.

Among all the applications studied in this report, in 2024, the diagnostic applications segment is expected to account for a larger share of the ELISA market. ELISA is widely used in clinical settings for the identification of infectious diseases, allergies, cancer, autoimmune diseases, and drug discovery. High demand for ELISA kits for disease diagnosis and high adoption of self-testing pregnancy kits due to their wide availability in pharmacies at low prices support the largest share of the market.

Among all the end users studied in this report, in 2024, the diagnostic laboratories segment is expected to account for a larger share of the ELISA market. The segment's largest share is attributed to the high burden of chronic diseases, the rising number of diagnostic laboratories, and supportive initiatives to advance clinical testing capabilities in countries. For instance, according to the Science and Medicine Group (U.S.), in July 2024, Danaher announced the launch of CLIA and College of American Pathologists-certified labs for research and development in companion diagnostics and complementary diagnostics. The first two labs will be opened in Newcastle, the U.K., and the second lab will be opened in the U.S.

An in-depth analysis of the geographical scenario of the ELISA market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is expected to account for the largest share of 37.7% of the ELISA market. The large share of this regional market is attributed to the well-established healthcare infrastructure, high investment in R&D activities, high prevalence of chronic diseases, a large number of diagnostic and pathology laboratories, and the presence of key market players in the region. For instance, in December 2022, Labcorp (U.S.) launched an anatomic pathology and histology (APH) laboratory in Los Angeles, the U.S.

Scope of the Report:

ELISA Market Assessment-by Type

Direct ELISA
Indirect ELISA
Sandwich ELISA
Competitive ELISA

ELISA Market Assessment-by Offering

Kits & Assays
Analyzers
- By Mode
Fully Automated
Semi-automated
- By Type
Optical Grating ELISA Analyzers
Optical Filter ELISA Analyzers
Software

ELISA Market Assessment-by Technology

Chemiluminescence ELISA
Colorimetric ELISA
Fluorescence ELISA

ELISA Market Assessment-by Application

Research Applications
- Drug Discovery & Monitoring
Protein Quantification
Antibody Detection
Biomarker Discovery
Other Drug Discovery & Monitoring Applications
- Vaccine Development
Diagnostic Applications
- Infectious Diseases
- Autoimmune Diseases
- Oncology
- Other Diagnostic Applications
Food Testing
Other Applications

Note: Other drug discovery & monitoring applications include toxicology studies and quality control.

Note: Other diagnostics applications include allergen testing and pregnancy testing.

Note: Other applications include agricultural, environmental, veterinary, and forensic applications.

ELISA Market Assessment-by End User

Hospitals & Clinics
Ambulatory Surgical Centres
Pharmaceutical & Biotechnology Companies
Diagnostic Laboratories
CROs & CDMOs
Academic & Research Institutes
Food Laboratories
Other End Users

Note: Other end users include home healthcare, the agriculture industry, and the forensics industry.

ELISA Market Assessment-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K
- Italy
- Spain
- Switzerland
- Belgium
- Rest of Europe (RoE)
Asia-Pacific (APAC)
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific (RoAPAC)
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa

Product Code: MRHC - 1041314

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Data Collection & Validation Process
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing & Forecasting
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Drivers
- 4.2.1. High Burden of Chronic & Infectious Diseases
- 4.2.2. Use of ELISA in Clinical Applications
- 4.2.3. Advancements in ELISA
- 4.2.4. Use of ELISA in the Food Industry
4.3. Restraints
- 4.3.1. Possibility of False Positive Results
- 4.3.2. High Costs of ELISA Antibody Preparation
4.4. Opportunities
- 4.4.1. Increasing Focus on Vaccine Development
- 4.4.2. Growing Research Activities in Developing Countries
- 4.4.3. Increasing R&D for Biomarker Detection
4.5. Challenges
- 4.5.1. Stringent Regulations for Approval
- 4.5.2. Use of Alternative Technologies for Disease Diagnosis
4.6. Factor Analysis
4.7. Trends
- 4.7.1. Digital ELISA
- 4.7.2. Robotics & Automation
- 4.7.3. Multiplex ELISA
4.8. Regulatory Analysis
4.9. Pricing Analysis
4.10. Porter's Five Forces Analysis

5. ELISA Market Assessment-by Type

5.1. Overview
5.2. Direct ELISA
5.3. Indirect ELISA
5.4. Sandwich ELISA
5.5. Competitive ELISA

6. ELISA Market Assessment-by Offering

6.1. Overview
6.2. Kits & Assays
6.3. Analyzers
- 6.3.1. By Mode
  - 6.3.1.1. Fully Automated
  - 6.3.1.2. Semi-automated
- 6.3.2. By Type
  - 6.3.2.1. Optical Grating ELISA Analyzers
  - 6.3.2.2. Optical Filter ELISA Analyzers
6.4. Software

7. ELISA Market Assessment-by Technology

7.1. Overview
7.2. Chemiluminescence ELISA
7.3. Colorimetric ELISA
7.4. Fluorescence ELISA

8. ELISA Market Assessment-by Application

8.1. Overview
8.2. Research Applications
- 8.2.1. Drug Discovery & Monitoring
  - 8.2.1.1. Protein Quantification
  - 8.2.1.2. Antibody Detection
  - 8.2.1.3. Biomarker Discovery
  - 8.2.1.4. Other Drug Discovery & Monitoring Applications
- 8.2.2. Vaccine Development
8.3. Diagnostic Applications
- 8.3.1. Infectious Diseases
- 8.3.2. Autoimmune Diseases
- 8.3.3. Oncology
- 8.3.4. Other Diagnostic Applications
8.4. Food Testing
8.5. Other Applications

9. ELISA Market Assessment-by End User

9.1. Overview
9.2. Pharmaceutical & Biotechnology Companies
9.3. Diagnostic Laboratories
9.4. CDMOs & CROs
9.5. Academic & Research Institutes
9.6. Food Laboratories
9.7. Other End Users

10. ELISA Market Assessment-by Geography

10.1. Overview
10.2. North America
- 10.2.1. U.S.
- 10.2.2. Canada
10.3. Europe
- 10.3.1. Germany
- 10.3.2. France
- 10.3.3. U.K.
- 10.3.4. Italy
- 10.3.5. Spain
- 10.3.6. Switzerland
- 10.3.7. Belgium
- 10.3.8. Rest of Europe (RoE)
10.4. Asia-Pacific
- 10.4.1. Japan
- 10.4.2. China
- 10.4.3. India
- 10.4.4. South Korea
- 10.4.5. Australia
- 10.4.6. Rest of Asia-Pacific (RoAPAC)
10.5. Latin America
- 10.5.1. Brazil
- 10.5.2. Mexico
- 10.5.3. Rest of Latin America (RoLATAM)
10.6. Middle East & Africa

11. Competition Analysis

11.1. Overview
11.2. Key Growth Strategies of Leading Players
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
- 11.4.1. Industry Leaders
- 11.4.2. Market Differentiators
- 11.4.3. Vanguards
- 11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Rankings of Key Players (2023)

12. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis)

12.1. Thermo Fisher Scientific Inc.
12.2. Merck KGaA
12.3. Bio-Rad Laboratories, Inc.
12.4. F. Hoffmann-La Roche AG
12.5. Danaher Corporation
12.6. QIAGEN N.V.
12.7. Agilent Technologies, Inc.
12.8. Abbott Laboratories
12.9. bioMerieux SA
12.10. Revvity, Inc.
12.11. QuidelOrtho Corporation
12.12. Becton, Dickinson and Company
12.13. Repligen Corporation
12.14. BioLegend
12.15. Bio-Techne Corporation

(Note: SWOT analysis will be provided for the top 5 companies.)

13. Appendix

13.1. Available Customization
13.2. Related Reports